PTC Therapeutics Inc. (PTCT)’s Financial Results Comparing With Seres Therapeutics Inc. (NASDAQ:MCRB)

PTC Therapeutics Inc. (NASDAQ:PTCT) and Seres Therapeutics Inc. (NASDAQ:MCRB) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PTC Therapeutics Inc. 256.43M 6.64 78.48M -1.70 0.00
Seres Therapeutics Inc. 20.69M 11.83 106.61M -2.62 0.00

In table 1 we can see PTC Therapeutics Inc. and Seres Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides us PTC Therapeutics Inc. and Seres Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
PTC Therapeutics Inc. -30.60% -32.7% -13.6%
Seres Therapeutics Inc. -515.27% 0% -72.2%

Risk & Volatility

PTC Therapeutics Inc. has a 2.26 beta, while its volatility is 126.00%, thus making it more volatile than Standard and Poor’s 500. Competitively, Seres Therapeutics Inc.’s beta is 0.67 which is 33.00% less volatile than Standard and Poor’s 500.


PTC Therapeutics Inc.’s Current Ratio and Quick Ratio are 2.7 and 2.6 respectively. The Current Ratio and Quick Ratio of its competitor Seres Therapeutics Inc. are 2 and 2 respectively. PTC Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Seres Therapeutics Inc.

Analyst Recommendations

PTC Therapeutics Inc. and Seres Therapeutics Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PTC Therapeutics Inc. 0 1 3 2.75
Seres Therapeutics Inc. 0 0 1 3.00

The average price target of PTC Therapeutics Inc. is $50, with potential upside of 68.35%. Competitively Seres Therapeutics Inc. has a consensus price target of $15, with potential upside of 150.42%. Based on the analysts belief we can conclude, Seres Therapeutics Inc. is looking more favorable than PTC Therapeutics Inc.

Institutional & Insider Ownership

The shares of both PTC Therapeutics Inc. and Seres Therapeutics Inc. are owned by institutional investors at 94.5% and 78.7% respectively. PTC Therapeutics Inc.’s share held by insiders are 3.31%. On the other hand, insiders held about 0.7% of Seres Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PTC Therapeutics Inc. -2.82% -5.5% -26.52% -9.04% 106.09% 106.95%
Seres Therapeutics Inc. -11.5% -8.65% -12.6% -13.87% -26.54% -27.12%

For the past year PTC Therapeutics Inc. had bullish trend while Seres Therapeutics Inc. had bearish trend.


PTC Therapeutics Inc. beats on 8 of the 12 factors Seres Therapeutics Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companyÂ’s lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companyÂ’s product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.